Cervical cancer

Summary

Cervical cancer (MONDO:0002974) is a cancer (an umbrella term covering 9 Mondo subtypes) with 7 cohort genes (36 GWAS associations across 15 studies; 7 CIViC-evidence somatic drivers; 36 ClinVar predisposition records) and 1,662 clinical trials. Molecularly, XRCC1 Q399R confers sensitivity to Cisplatin + Carboplatin in Cervical Cancer (CIViC Level B); 3 further subtype–drug associations are mapped below. Top therapeutic interventions include cisplatin, human papillomavirus, l1 protein virus like particles, and topotecan.

At a glance

• Classification: Cancer
• Umbrella term: 9 Mondo subtypes
• Cohort genes: 7
• GWAS associations: 36
• ClinVar variants: 36
• Clinical trials: 1,662
• Precision-medicine evidence (CIViC): 4 subtype–drug associations

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cervical cancer
Mondo ID	MONDO:0002974
OMIM	603956
DOID	DOID:4362
ICD-10-CM	C53
ICD-11	1256072522
NCIT	C9311
SNOMED CT	363354003
UMLS	C4048328
MedGen	890252
Anatomy (UBERON)	UBERON:0000002
Is cancer (heuristic)	yes

Also known as: cancer of uterine cervix · cervical cancer, somatic · cervical neoplasm · malignant cervical neoplasm · malignant cervical tumor · malignant cervical tumour · malignant cervix neoplasm · malignant cervix tumor · malignant cervix tumour · malignant cervix uteri neoplasm · malignant cervix uteri tumor · malignant cervix uteri tumour · malignant neoplasm of cervix · malignant neoplasm of cervix uteri · malignant neoplasm of the cervix · malignant neoplasm of the cervix uteri · malignant neoplasm of the uterine cervix · malignant neoplasm of uterine cervix · malignant tumor of cervix · malignant tumor of cervix uteri (+17 more)

Data availability: 36 ClinVar variants · 36 GWAS associations (15 studies).

Disease family

An umbrella term covering 9 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › female reproductive organ cancer › uterine cancer › cervical cancer

Related subtypes (6): uterine adnexa cancer, placenta cancer, uterine carcinoma, uterine corpus cancer, uterine carcinosarcoma, endometrial cancer

Subtypes (9): cervix melanoma, uterine ligament cancer, cervical carcinoma, cervical Wilms tumor, high-grade neuroendocrine carcinoma of the cervix uteri, malignant mixed epithelial and mesenchymal tumor of cervix uteri, sarcoma of cervix uteri, malignant germ cell tumor of cervix uteri, malignant neoplasm of endocervix

Genetics & variants

GWAS landscape

36 GWAS associations across 15 studies. Top hits map to 19 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs28718232	3e-44	HLA-DQA1 - HLA-DQB1	?
rs35508382	1e-39	HLA-DRB1 - HLA-DQA1	G
rs4849177	1e-15	PAX8, PAX8-AS1	C	0.87
rs27069	6e-15	CLPTM1L - LINC01511	T	0.88
rs1126513	3e-12	HLA-DPB1, HLA-DPA1	?
rs12603332	2e-10	ORMDL3	C	0.9
rs1126506	2e-08	HLA-DPB1, HLA-DPA1	?
rs2268177	3e-08	CDC42	T
rs425787	4e-08	Y_RNA - CD70	?
rs225902	1e-07	PRKD1	A	0.47
rs17151352	2e-07	MAGI2	T	20
rs74388374	5e-07	OSBPL10	G	24
rs28631719	2e-06	HLA-DQA1 - HLA-DQB1	A	0.57
rs1012780	2e-06	CKAP2LP1 - SIRPA	C	2.7
rs11166844	3e-06	COL22A1	T	0.64
rs148042118	3e-06	LINC01982 - LINC02089	G	2.39
rs2741873	3e-06	OSGIN1	C	0.52
rs1942084	3e-06	KC6	T	2.89
rs111761582	3e-06	COL18A1	C	47.14
rs68058549	3e-06	GPC5	G	26.61
rs2937268	3e-06	PDE4B	C	27.93
rs72233830	3e-06		TGA	12.65
rs17035086	3e-06	LINC02272 - PDGFC	T	21.33
rs72801535	3e-06	STOX1	C	84.52
rs73174350	4e-06	MECOM	G	30.18
rs62441892	4e-06	AGR2 - AGR3	C	24.03
rs6535608	4e-06	NR3C2 - ASS1P8	C	15.37
rs11706806	4e-06	ZNF385D	G	16.61
rs2299059	4e-06	JARID2	A	16.59
rs17048658	5e-06	ISCA1P6 - LINC01854	A	0.51

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90266933	Koel M	2023	14,694	551,136	GWAS meta-analyses clarify genetics of cervical phenotypes and inform risk stratification for cervical cancer.
GCST90246358	Koel M	2023	8,624	400,573	GWAS meta-analyses clarify genetics of cervical phenotypes and inform risk stratification for cervical cancer.
GCST90246359	Koel M	2023	8,624	400,573	GWAS meta-analyses clarify genetics of cervical phenotypes and inform risk stratification for cervical cancer.
GCST90435605	Zhou W	2018	3,653	381,902	Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90651227	Liu TY	2025	2,931	111,969	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90077634	Backman JD	2021	1,786	37,828	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90081620	Backman JD	2021	1,786	37,828	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90477203	Verma A	2024	1,775	30,185	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90435606	Zhou W	2018	1,659	381,902	Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90477202	Verma A	2024	802	15,352	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	1
Tier 2: splice/UTR	3
Tier 3: regulatory	0
Tier 4: intronic/intergenic	27

MAF distribution

Bucket	Variants
common (>=0.05)	24
low_freq (0.01-0.05)	7
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intron_variant	18
intergenic_variant	7
non_coding_transcript_exon_variant	1
stop_gained	1
5_prime_UTR_variant	1
splice_region_variant	1
3_prime_UTR_variant	1
unknown	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs28718232	6	32658973	A>G	0.05	intergenic_variant	HLA-DQA1 - HLA-DQB1	3e-44	Tier 4: intronic/intergenic
rs35508382	6	32625367	A>G	0.05	intergenic_variant	HLA-DRB1 - HLA-DQA1	1e-39	Tier 4: intronic/intergenic
rs4849177	2	113225007	T>A,C	0.39	intron_variant	PAX8, PAX8-AS1	1e-15	Tier 4: intronic/intergenic
rs27069	5	1347013	C>T	0.43	non_coding_transcript_exon_variant	CLPTM1L - LINC01511	6e-15	Tier 4: intronic/intergenic
rs1126513	6	33080690	G>T	0.05	stop_gained	HLA-DPB1, HLA-DPA1	3e-12	Tier 1: coding
rs12603332	17	39926554	T>C	0.49	5_prime_UTR_variant	ORMDL3	2e-10	Tier 2: splice/UTR
rs1126506	6	33080682	T>C,G	0.05	splice_region_variant	HLA-DPB1, HLA-DPA1	2e-08	Tier 2: splice/UTR
rs2268177	1	22088917	A>C,G,T	0.05	3_prime_UTR_variant	CDC42	3e-08	Tier 2: splice/UTR
rs425787	19	6578940	T>A,C,G	0.05	intergenic_variant	Y_RNA - CD70	4e-08	Tier 4: intronic/intergenic
rs225902	14	29990245	A>G,T	0.154	intron_variant	PRKD1	1e-07	Tier 4: intronic/intergenic
rs17151352	7	78716998	T>C	0.127	intron_variant	MAGI2	2e-07	Tier 4: intronic/intergenic
rs74388374	3	31878861	G>A	0.116	intron_variant	OSBPL10	5e-07	Tier 4: intronic/intergenic
rs28631719	6	32657632	A>G	0.426	intergenic_variant	HLA-DQA1 - HLA-DQB1	2e-06	Tier 4: intronic/intergenic
rs1012780	20	1774323	C>G,T	0.087	intron_variant	CKAP2LP1 - SIRPA	2e-06	Tier 4: intronic/intergenic
rs11166844	8	138766637	C>A,G,T	0.423	intron_variant	COL22A1	3e-06	Tier 4: intronic/intergenic
rs148042118	17	52737990	G>GT	0.067	intron_variant	LINC01982 - LINC02089	3e-06	Tier 4: intronic/intergenic
rs2741873	16	83957967	C>A,G,T	0.262	intron_variant	OSGIN1	3e-06	Tier 4: intronic/intergenic
rs1942084	18	41568225	T>A	0.041	intron_variant	KC6	3e-06	Tier 4: intronic/intergenic
rs111761582	21	45461787	C>A	0.024	intron_variant	COL18A1	3e-06	Tier 4: intronic/intergenic
rs68058549	13	91618423	G>C,T	0.042	intron_variant	GPC5	3e-06	Tier 4: intronic/intergenic
rs2937268	1	66087924	C>G,T	0.062	intron_variant	PDE4B	3e-06	Tier 4: intronic/intergenic
rs72233830				0.014			3e-06	Tier 4: intronic/intergenic
rs17035086	4	156696327	T>A	0.082	intergenic_variant	LINC02272 - PDGFC	3e-06	Tier 4: intronic/intergenic
rs72801535	10	68872285	C>T	0.036	intron_variant	STOX1	3e-06	Tier 4: intronic/intergenic
rs73174350	3	169552715	G>A	0.037	intron_variant	MECOM	4e-06	Tier 4: intronic/intergenic
rs62441892	7	16835876	C>T	0.072	intron_variant	AGR2 - AGR3	4e-06	Tier 4: intronic/intergenic
rs6535608	4	148454471	C>A	0.478	intron_variant	NR3C2 - ASS1P8	4e-06	Tier 4: intronic/intergenic
rs11706806	3	21690952	G>A,C	0.276	intron_variant	ZNF385D	4e-06	Tier 4: intronic/intergenic
rs2299059	6	15376763	A>G,T	0.254	intron_variant	JARID2	4e-06	Tier 4: intronic/intergenic
rs17048658	2	128647548	A>C,G	0.177	intergenic_variant	ISCA1P6 - LINC01854	5e-06	Tier 4: intronic/intergenic

ClinVar germline variants

36 retrieved; paginated sample, class counts are floors:

12 uncertain significance, 9 pathogenic, 6 conflicting classifications of pathogenicity, 5 benign/likely benign, 4 pathogenic/likely pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
16327	NM_000142.5(FGFR3):c.1138G>A (p.Gly380Arg)	FGFR3	Pathogenic	criteria provided, multiple submitters, no conflicts
16331	NM_000142.5(FGFR3):c.1948A>G (p.Lys650Glu)	FGFR3	Pathogenic	criteria provided, multiple submitters, no conflicts
16332	NM_000142.5(FGFR3):c.742C>T (p.Arg248Cys)	FGFR3	Pathogenic	criteria provided, multiple submitters, no conflicts
16335	NM_000142.5(FGFR3):c.2419T>A (p.Ter807Arg)	FGFR3	Pathogenic	criteria provided, multiple submitters, no conflicts
16338	NM_000142.5(FGFR3):c.1620C>G (p.Asn540Lys)	FGFR3	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
16339	NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys)	FGFR3	Pathogenic	criteria provided, multiple submitters, no conflicts
16340	NM_000142.5(FGFR3):c.749C>G (p.Pro250Arg)	FGFR3	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
16341	NM_000142.5(FGFR3):c.1949A>T (p.Lys650Met)	FGFR3	Pathogenic	criteria provided, multiple submitters, no conflicts
16347	NM_000142.5(FGFR3):c.1950G>C (p.Lys650Asn)	FGFR3	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
16359	NM_000142.5(FGFR3):c.1108G>T (p.Gly370Cys)	FGFR3	Pathogenic	criteria provided, multiple submitters, no conflicts
65562	NM_000142.5(FGFR3):c.2420G>T (p.Ter807Leu)	FGFR3	Pathogenic	criteria provided, multiple submitters, no conflicts
65855	NM_000142.5(FGFR3):c.1949A>C (p.Lys650Thr)	FGFR3	Pathogenic	criteria provided, multiple submitters, no conflicts
12352	NM_000546.6(TP53):c.747G>T (p.Arg249Ser)	TP53	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
128194	NM_032043.3(BRIP1):c.587A>G (p.Asn196Ser)	BRIP1	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1680106	NM_000142.5(FGFR3):c.1827C>G (p.Ala609=)	FGFR3	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
287276	NM_000142.5(FGFR3):c.598C>T (p.Arg200Cys)	FGFR3	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
521225	NM_000142.5(FGFR3):c.2153A>G (p.Asn718Ser)	FGFR3	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
546226	NM_000142.5(FGFR3):c.200G>A (p.Gly67Asp)	FGFR3	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
579912	NM_000142.5(FGFR3):c.2005C>G (p.Arg669Gly)	FGFR3	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1309951	NM_000142.5(FGFR3):c.1255C>T (p.Leu419Phe)	FGFR3	Uncertain significance	criteria provided, multiple submitters, no conflicts
1310646	NM_000142.5(FGFR3):c.1547A>G (p.Asp516Gly)	FGFR3	Uncertain significance	criteria provided, multiple submitters, no conflicts
1680065	NM_000142.5(FGFR3):c.1267G>C (p.Val423Leu)	FGFR3	Uncertain significance	criteria provided, multiple submitters, no conflicts
1680111	NM_000142.5(FGFR3):c.1946A>G (p.Lys649Arg)	FGFR3	Uncertain significance	criteria provided, multiple submitters, no conflicts
1684285	NM_000142.5(FGFR3):c.184C>T (p.Pro62Ser)	FGFR3	Uncertain significance	criteria provided, multiple submitters, no conflicts
1691355	NM_000142.5(FGFR3):c.1718C>T (p.Pro573Leu)	FGFR3	Uncertain significance	criteria provided, multiple submitters, no conflicts
2874249	NM_000142.5(FGFR3):c.2105A>T (p.Glu702Val)	FGFR3	Uncertain significance	criteria provided, multiple submitters, no conflicts
3892110	NM_000142.5(FGFR3):c.166G>A (p.Ala56Thr)	FGFR3	Uncertain significance	criteria provided, single submitter
465350	NM_000142.5(FGFR3):c.1993G>T (p.Ala665Ser)	FGFR3	Uncertain significance	criteria provided, multiple submitters, no conflicts
533891	NM_000142.5(FGFR3):c.2294C>T (p.Ala765Val)	FGFR3	Uncertain significance	criteria provided, multiple submitters, no conflicts
651478	NM_000142.5(FGFR3):c.2413C>T (p.Arg805Trp)	FGFR3	Uncertain significance	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 50 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
TP53	LoF	ACC,ALL,AML,ANGS,ANSC,BCC,BL,BLADDER,BLCA,BRCA,CCRCC,CEAD,CESC,CHOL,CHRCC,CLLSLL,COAD,COADREAD,CSCC,DLBCLNOS,EGC,ES,ESCA,ESCC,GB,GBC,GBM,GIST,HCC,HGGNOS,HNSC,LGGNOS,LIPO,LMS,LNM,LUAD,LUSC,MBL,MEL,MLYM,MT,NBL,NETNOS,NHL,NPC,NSCLC,OS,OVT,PAAD,PANCREAS,PAST,PCM,PLMESO,PRAD,PRCC,PROSTATE,RCC,READ,SACA,SARCNOS,SCLC,SIC,SKCM,SKIN,SOFT_TISSUE,STAD,STOMACH,THYM,UCEC,UCS,UTUC,VULVA,WDTC,WT	CIViC #45
SPHK1			CIViC #7041
XRCC1			CIViC #6144
CD44			CIViC #855
PIK3CA	Act	ACYC,ANGS,ANSC,BCC,BLADDER,BLCA,BRCA,CCRCC,CEAD,CESC,CHOL,COAD,COADREAD,EPM,ESCA,ESCC,GB,GBM,HCC,HGGNOS,HNSC,LGGNOS,LIPO,LMS,LUAD,LUSC,MBL,MGCT,NPC,NSCLC,OVT,PAAD,PAST,PLMESO,PRAD,PRCC,PROSTATE,RCC,SACA,SKCM,SOFT_TISSUE,STAD,UCEC,UCS,UTUC,VULVA,WDTC	CIViC #37
BRIP1			CIViC #15955
FGFR3	Act	BLADDER,BLCA,HNSC,LUSC,PCM,PLMESO,UTUC	CIViC #23

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
TP53	Orphanet:1333	Familial pancreatic carcinoma
TP53	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
TP53	Orphanet:1501	Adrenocortical carcinoma
TP53	Orphanet:210159	Adult hepatocellular carcinoma
TP53	Orphanet:251576	Gliosarcoma
TP53	Orphanet:251579	Giant cell glioblastoma
TP53	Orphanet:251899	Choroid plexus carcinoma
TP53	Orphanet:2807	Papilloma of choroid plexus
TP53	Orphanet:293199	Pleomorphic rhabdomyosarcoma
TP53	Orphanet:3318	Essential thrombocythemia
TP53	Orphanet:524	Li-Fraumeni syndrome
TP53	Orphanet:52688	Myelodysplastic syndrome
TP53	Orphanet:585909	B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)
TP53	Orphanet:667662	Breast implant-associated anaplastic large cell lymphoma
TP53	Orphanet:668	Osteosarcoma
TP53	Orphanet:67038	B-cell chronic lymphocytic leukemia
TP53	Orphanet:70573	Small cell lung cancer
TP53	Orphanet:96253	Cushing disease
TP53	Orphanet:99756	Alveolar rhabdomyosarcoma
TP53	Orphanet:99757	Embryonal rhabdomyosarcoma
PIK3CA	Orphanet:140944	CLOVES syndrome
PIK3CA	Orphanet:144	Lynch syndrome
PIK3CA	Orphanet:168984	CLAPO syndrome
PIK3CA	Orphanet:201	Cowden syndrome
PIK3CA	Orphanet:210159	Adult hepatocellular carcinoma
PIK3CA	Orphanet:221061	Familial cerebral cavernous malformation
PIK3CA	Orphanet:2495	Meningioma
PIK3CA	Orphanet:276280	Hemihyperplasia-multiple lipomatosis syndrome
PIK3CA	Orphanet:295239	Macrodactyly of fingers, unilateral
PIK3CA	Orphanet:295243	Macrodactyly of toes, unilateral
PIK3CA	Orphanet:314662	Segmental progressive overgrowth syndrome with fibroadipose hyperplasia
PIK3CA	Orphanet:60040	Megalencephaly-capillary malformation-polymicrogyria syndrome
PIK3CA	Orphanet:714737	Diffuse capillary malformation with overgrowth
PIK3CA	Orphanet:90308	Capillary-lymphatic-venous malformation with segmental distribution
PIK3CA	Orphanet:99802	Hemimegalencephaly
BRIP1	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
BRIP1	Orphanet:84	Fanconi anemia
FGFR3	Orphanet:15	Achondroplasia
FGFR3	Orphanet:1860	Thanatophoric dysplasia type 1
FGFR3	Orphanet:2363	Lacrimoauriculodentodigital syndrome
FGFR3	Orphanet:251576	Gliosarcoma
FGFR3	Orphanet:251579	Giant cell glioblastoma
FGFR3	Orphanet:35099	Non-syndromic bicoronal craniosynostosis
FGFR3	Orphanet:429	Hypochondroplasia
FGFR3	Orphanet:53271	Muenke syndrome
FGFR3	Orphanet:794	Saethre-Chotzen syndrome
FGFR3	Orphanet:85164	Camptodactyly-tall stature-scoliosis-hearing loss syndrome
FGFR3	Orphanet:85165	Severe achondroplasia-developmental delay-acanthosis nigricans syndrome
FGFR3	Orphanet:93262	Crouzon syndrome-acanthosis nigricans syndrome
FGFR3	Orphanet:93274	Thanatophoric dysplasia type 2

Cohort genes → proteins

7 cohort genes, 7 distinct canonical proteins.

Evidence partition

Subset	Genes
civic_only	4
multi_evidence	3

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
TP53	HGNC:11998	ENSG00000141510	P04637	Cellular tumor antigen p53	clinvar,civic_evidence
SPHK1	HGNC:11240	ENSG00000176170	Q9NYA1	Sphingosine kinase 1	civic_evidence
XRCC1	HGNC:12828	ENSG00000073050	P18887	DNA repair protein XRCC1	civic_evidence
CD44	HGNC:1681	ENSG00000026508	P16070	CD44 antigen	civic_evidence
PIK3CA	HGNC:8975	ENSG00000121879	P42336	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	civic_evidence
BRIP1	HGNC:20473	ENSG00000136492	Q9BX63	Fanconi anemia group J protein	clinvar
FGFR3	HGNC:3690	ENSG00000068078	P22607	Fibroblast growth factor receptor 3	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
TP53	Cellular tumor antigen p53	Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence.
SPHK1	Sphingosine kinase 1	Catalyzes the phosphorylation of sphingosine to form sphingosine 1-phosphate (SPP), a lipid mediator with both intra- and extracellular functions.
XRCC1	DNA repair protein XRCC1	Scaffold protein involved in DNA single-strand break repair by mediating the assembly of DNA break repair protein complexes.
CD44	CD44 antigen	Cell-surface receptor that plays a role in cell-cell interactions, cell adhesion and migration, helping them to sense and respond to changes in the tissue microenvironment.
PIK3CA	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Phosphoinositide-3-kinase (PI3K) phosphorylates phosphatidylinositol (PI) and its phosphorylated derivatives at position 3 of the inositol ring to produce 3-phosphoinositides.
BRIP1	Fanconi anemia group J protein	DNA-dependent ATPase and 5’-3’ DNA helicase required for the maintenance of chromosomal stability.
FGFR3	Fibroblast growth factor receptor 3	Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis.

Protein-family classification

Druggable: 4 · Difficult: 1 · Unknown: 2 · Druggable fraction: 0.57

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	3	11.9×	0.006
Enzyme (other)	1	1.7×	0.793
Transcription factor	1	1.2×	0.793
Other/Unknown	2	0.5×	0.968

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
TP53	Transcription factor	no		p53_tumour_suppressor, p53-like_TF_DNA-bd_sf, p53_tetrameristn
SPHK1	Kinase	yes	2.7.1.91	Diacylglycerol_kinase_cat_dom, NAD/diacylglycerol_kinase_sf, ATP-NAD_kinase_N
XRCC1	Other/Unknown	no		BRCT_dom, Xrcc1_N, Galactose-bd-like_sf
CD44	Other/Unknown	no		Link_dom, CD44_antigen, C-type_lectin-like/link_sf
PIK3CA	Kinase	yes	2.7.1.137	PI3K_Ras-bd_dom, PI3/4_kinase_cat_dom, PI3K_accessory_dom
BRIP1	Enzyme (other)	yes	3.6.4.12	Helicase-like_DEXD_c2, ATP-dep_Helicase_C, RAD3-like_helicase_DEAD
FGFR3	Kinase	yes	2.7.10.1	Prot_kinase_dom, Ser-Thr/Tyr_kinase_cat_dom, Ig_sub2

Expression context

Cohort genes with no expression data: 0.

7 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	7
unknown	0

Top tissues across cohort

Tissue	Cohort genes
ventricular zone	3
ganglionic eminence	2
tendon of biceps brachii	2
stromal cell of endometrium	2
lower esophagus mucosa	1
tibial nerve	1
mammalian vulva	1
parotid gland	1
adrenal tissue	1
calcaneal tendon	1
tendon	1
male germ line stem cell (sensu Vertebrata) in testis	1
primordial germ cell in gonad	1
skin of hip	1
upper arm skin	1
upper leg skin	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
TP53	223	ubiquitous	marker	ventricular zone, ganglionic eminence, tendon of biceps brachii
SPHK1	210	ubiquitous	marker	stromal cell of endometrium, lower esophagus mucosa, tibial nerve
XRCC1	276	ubiquitous	marker	ventricular zone, tendon of biceps brachii, ganglionic eminence
CD44	294	ubiquitous	marker	parotid gland, stromal cell of endometrium, mammalian vulva
PIK3CA	284	ubiquitous	marker	calcaneal tendon, adrenal tissue, tendon
BRIP1	181	ubiquitous	marker	ventricular zone, primordial germ cell in gonad, male germ line stem cell (sensu Vertebrata) in testis
FGFR3	262	broad	marker	upper leg skin, skin of hip, upper arm skin

Protein interactions among cohort

Intra-cohort edges: 1.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
TP53	22,736
CD44	6,810
PIK3CA	5,157
FGFR3	4,510
XRCC1	2,591
SPHK1	2,277
BRIP1	2,272

Intra-cohort edges

A	B	Sources
FGFR3	PIK3CA	string_interaction

Structural data

PDB: 7 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
TP53	P04637	313
PIK3CA	P42336	135
FGFR3	P22607	15
XRCC1	P18887	13
CD44	P16070	6
SPHK1	Q9NYA1	5
BRIP1	Q9BX63	3

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 164. Enrichment computed across 7 evidence-associated genes (7 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 7 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
PI-3K cascade:FGFR3	2	181.3×	0.007	FGFR3, PIK3CA
Signaling by FGFR3 in disease	2	141.9×	0.007	FGFR3, PIK3CA
Association of TriC/CCT with target proteins during biosynthesis	2	83.7×	0.011	TP53, SPHK1
PI3K Cascade	2	77.7×	0.011	FGFR3, PIK3CA
t(4;14) translocations of FGFR3	1	1631.4×	0.014	FGFR3
Signaling by FGFR3 fusions in cancer	1	1631.4×	0.014	FGFR3
Loss of function of TP53 in cancer due to loss of tetramerization ability	1	1631.4×	0.014	TP53
Extra-nuclear estrogen signaling	2	48.7×	0.014	SPHK1, PIK3CA
Regulation of TP53 Expression	1	815.7×	0.015	TP53
Signaling by ALK fusions and activated point mutants	2	42.9×	0.015	TP53, PIK3CA
PKR-mediated signaling	2	40.3×	0.015	TP53, SPHK1
VEGFA-VEGFR2 Pathway	2	39.8×	0.015	SPHK1, PIK3CA
Constitutive Signaling by Aberrant PI3K in Cancer	2	36.2×	0.015	FGFR3, PIK3CA
G2/M DNA damage checkpoint	2	34.4×	0.015	TP53, BRIP1
Interferon Signaling	2	34.4×	0.015	SPHK1, CD44
Regulation of TP53 Activity through Phosphorylation	2	33.6×	0.015	TP53, BRIP1
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	2	27.6×	0.021	FGFR3, PIK3CA
Transcriptional activation of cell cycle inhibitor p21	1	407.9×	0.022	TP53
Resolution of AP sites via the single-nucleotide replacement pathway	1	326.3×	0.026	XRCC1
Activation of NOXA and translocation to mitochondria	1	271.9×	0.026	TP53
MET activates PI3K/AKT signaling	1	271.9×	0.026	PIK3CA
Activated NTRK3 signals through PI3K	1	271.9×	0.026	PIK3CA
FGFR3b ligand binding and activation	1	233.1×	0.026	FGFR3
APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway	1	233.1×	0.026	XRCC1
RUNX3 regulates CDKN1A transcription	1	233.1×	0.026	TP53
Activated NTRK2 signals through PI3K	1	233.1×	0.026	PIK3CA
Signaling by LTK in cancer	1	233.1×	0.026	PIK3CA
PIP3 activates AKT signaling	2	19.1×	0.026	FGFR3, PIK3CA
PI3K/AKT activation	1	181.3×	0.027	PIK3CA
PI5P Regulates TP53 Acetylation	1	181.3×	0.027	TP53

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 7 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
double-strand break repair	3	87.0×	0.001	TP53, XRCC1, BRIP1
response to muscle inactivity	1	2407.4×	0.010	PIK3CA
sphingoid catabolic process	1	2407.4×	0.010	SPHK1
negative regulation of developmental growth	1	2407.4×	0.010	FGFR3
negative regulation of helicase activity	1	2407.4×	0.010	TP53
cellular response to actinomycin D	1	2407.4×	0.010	TP53
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	1	2407.4×	0.010	TP53
negative regulation of G1 to G0 transition	1	2407.4×	0.010	TP53
response to butyrate	1	2407.4×	0.010	PIK3CA
regulation of endosomal vesicle fusion	1	2407.4×	0.010	SPHK1
nucleotide-excision repair	2	109.4×	0.010	TP53, BRIP1
negative regulation of protein ADP-ribosylation	1	1203.7×	0.010	XRCC1
positive regulation of mitochondrial membrane permeability	1	1203.7×	0.010	TP53
oligodendrocyte apoptotic process	1	1203.7×	0.010	TP53
fibroblast growth factor receptor apoptotic signaling pathway	1	1203.7×	0.010	FGFR3
negative regulation of glucose catabolic process to lactate via pyruvate	1	1203.7×	0.010	TP53
regulation of base-excision repair	1	1203.7×	0.010	XRCC1
negative regulation of pentose-phosphate shunt	1	1203.7×	0.010	TP53
meiotic DNA double-strand break processing involved in reciprocal meiotic recombination	1	802.5×	0.010	BRIP1
obsolete homolactic fermentation	1	802.5×	0.010	TP53
response to L-leucine	1	802.5×	0.010	PIK3CA
monocyte aggregation	1	802.5×	0.010	CD44
bone maturation	1	802.5×	0.010	FGFR3
cellular response to hydrostatic pressure	1	802.5×	0.010	PIK3CA
signal transduction by p53 class mediator	1	802.5×	0.010	TP53
positive regulation of monocyte aggregation	1	802.5×	0.010	CD44
negative regulation of miRNA processing	1	802.5×	0.010	TP53
intrinsic apoptotic signaling pathway in response to hypoxia	1	802.5×	0.010	TP53
regulation of fibroblast apoptotic process	1	802.5×	0.010	TP53
regulation of lamellipodium morphogenesis	1	802.5×	0.010	CD44

Therapeutics

Drug target analysis

Approved (phase 4): 3 · Phase ≥3: 4 · Phased (≥1): 4 · Undrugged: 3

Druggability breadth: 5 of 7 evidence-associated genes (71%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
TP53	NITROFURANTOIN
PIK3CA	IDELALISIB
FGFR3	PONATINIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
TP53	196	4
PIK3CA	67	4
FGFR3	64	4
SPHK1	3	3
XRCC1	0	0
CD44	0	0
BRIP1	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
NITROFURANTOIN	4	TP53
DIOSMIN	4	TP53
VERTEPORFIN	4	TP53
CANDESARTAN CILEXETIL	4	TP53
DIENESTROL	4	TP53
CLOTRIMAZOLE	4	TP53
COLCHICINE	4	TP53
NABUMETONE	4	TP53
SALMETEROL XINAFOATE	4	TP53
AMIODARONE HYDROCHLORIDE	4	TP53
FURAZOLIDONE	4	TP53
AMOXAPINE	4	TP53
RALOXIFENE HYDROCHLORIDE	4	TP53
NICARDIPINE HYDROCHLORIDE	4	TP53
SULCONAZOLE NITRATE	4	TP53
PYRITHIONE ZINC	4	TP53
LACTIC ACID	4	TP53
OXYMETHOLONE	4	TP53
CHLOROXINE	4	TP53
PROPIOLACTONE	4	TP53
CLOMIPRAMINE HYDROCHLORIDE	4	TP53
PHENYL AMINOSALICYLATE	4	TP53
THIORIDAZINE HYDROCHLORIDE	4	TP53
AMITRIPTYLINE HYDROCHLORIDE	4	TP53
ETHOPROPAZINE HYDROCHLORIDE	4	TP53
MECHLORETHAMINE HYDROCHLORIDE	4	TP53
ECONAZOLE NITRATE	4	TP53
TRIFLUPROMAZINE HYDROCHLORIDE	4	TP53
PROCHLORPERAZINE EDISYLATE	4	TP53
DEQUALINIUM CHLORIDE	4	TP53

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 4.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
PIK3CA	2,034	Binding:2009, ADMET:19, Toxicity:4, Functional:2
FGFR3	975	Binding:948, Functional:18, ADMET:9
TP53	869	Binding:775, ADMET:83, Functional:10, Toxicity:1
SPHK1	232	Binding:228, ADMET:3, Functional:1
CD44	9	Binding:9

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
SPHK1	2.7.1.91	sphingosine kinase
PIK3CA	2.7.1.137, 2.7.1.153, 2.7.11.1	phosphatidylinositol 3-kinase, phosphatidylinositol-4,5-bisphosphate 3-kinase, non-specific serine/threonine protein kinase
BRIP1	3.6.4.12	DNA helicase
FGFR3	2.7.10.1	receptor protein-tyrosine kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
TP53	869
SPHK1	232
PIK3CA	2,034
FGFR3	975

Pharmacogenomics

Cohort genes with a PharmGKB record: 7; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

30 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
NITROFURANTOIN	4	TP53
DIOSMIN	4	TP53
VERTEPORFIN	4	TP53
CANDESARTAN CILEXETIL	4	TP53
DIENESTROL	4	TP53
CLOTRIMAZOLE	4	TP53
COLCHICINE	4	TP53
NABUMETONE	4	TP53
SALMETEROL XINAFOATE	4	TP53
AMIODARONE HYDROCHLORIDE	4	TP53
FURAZOLIDONE	4	TP53
AMOXAPINE	4	TP53
RALOXIFENE HYDROCHLORIDE	4	TP53
NICARDIPINE HYDROCHLORIDE	4	TP53
SULCONAZOLE NITRATE	4	TP53
PYRITHIONE ZINC	4	TP53
LACTIC ACID	4	TP53
OXYMETHOLONE	4	TP53
CHLOROXINE	4	TP53
PROPIOLACTONE	4	TP53
CLOMIPRAMINE HYDROCHLORIDE	4	TP53
PHENYL AMINOSALICYLATE	4	TP53
THIORIDAZINE HYDROCHLORIDE	4	TP53
AMITRIPTYLINE HYDROCHLORIDE	4	TP53
ETHOPROPAZINE HYDROCHLORIDE	4	TP53
MECHLORETHAMINE HYDROCHLORIDE	4	TP53
ECONAZOLE NITRATE	4	TP53
TRIFLUPROMAZINE HYDROCHLORIDE	4	TP53
PROCHLORPERAZINE EDISYLATE	4	TP53
DEQUALINIUM CHLORIDE	4	TP53

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	3	TP53, PIK3CA, FGFR3
B	Phased (≥1) drug, not yet approved	1	SPHK1
C	Druggable family + PDB, no drug	1	BRIP1
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	2	XRCC1, CD44

Undrugged target profiles

3 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
XRCC1	0	—
CD44	9	—
BRIP1	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 1,662.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	333
PHASE2	324
PHASE1	170
PHASE3	134
PHASE1/PHASE2	84
PHASE4	29
PHASE2/PHASE3	14
EARLY_PHASE1	12

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00923702	PHASE4	ACTIVE_NOT_RECRUITING	Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India
NCT04910802	PHASE4	RECRUITING	Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in Sweden
NCT06536855	PHASE4	NOT_YET_RECRUITING	Faster Elimination of HPV Infection and Cervical Cancer Using Concomitant HPV Vaccination and HPV Screening: A Demonstration Project in Rwanda
NCT06871787	PHASE4	NOT_YET_RECRUITING	Near-Infrared Fluorescence Imaging With Indocyanine Green to Evaluate Bowel Anastomoses in Gynecologic Oncology Surgery
NCT06952660	PHASE4	RECRUITING	Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
NCT07412873	PHASE4	NOT_YET_RECRUITING	Study on Sexual Health and Self-perceived Quality of Life (PROMs) in Patients Treated for Cervical Cancer
NCT00046969	PHASE4	COMPLETED	Epoetin Beta in Treating Anemia in Patients With Cervical Cancer
NCT00365508	PHASE4	COMPLETED	Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
NCT00613275	PHASE4	COMPLETED	Patient Navigation in the Safety Net:CONNECTeDD
NCT00629993	PHASE4	TERMINATED	Dissemination of Cervical Cancer Screening to Primary Care Physicians in Underserved Communities
NCT00666978	PHASE4	COMPLETED	Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking
NCT00862810	PHASE4	COMPLETED	Alternate Dosing Schedules Study for HPV Vaccine
NCT01021904	PHASE4	UNKNOWN	Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China
NCT01101750	PHASE4	COMPLETED	Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?
NCT01173900	PHASE4	COMPLETED	Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls
NCT01544478	PHASE4	COMPLETED	V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)
NCT01895517	PHASE4	COMPLETED	CervIcal Cancer Screening Trial by Randomization of HPV Testing Intervention for Upcoming Screening （CITRUS Study）
NCT01953107	PHASE4	COMPLETED	Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates.
NCT02296255	PHASE4	COMPLETED	Effect of HPV Vaccination on Women Aged 25 Years
NCT02629510	PHASE4	UNKNOWN	The Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP)
NCT02837926	PHASE4	COMPLETED	Comparing Health Services Interventions for the Prevention of HPV-related Cancer
NCT03206684	PHASE4	UNKNOWN	To Evaluate the Efficacy and Safety of PEG-rhG-CSF（Jinyouli®） in Reducing Neutropenia in Patients With Cervical Cancer
NCT03349463	PHASE4	UNKNOWN	Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers.
NCT03384511	PHASE4	COMPLETED	The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
NCT03423082	PHASE4	TERMINATED	Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer.
NCT03752606	PHASE4	COMPLETED	Application of Tachosil During Lymphadenectomy
NCT04819685	PHASE4	UNKNOWN	Application of KANG FU PEN in Radical Concurrent Radiotherapy and Chemotherapy for Cervical Cancer to Prevent and Treat Radiation-induced Rectal Injury
NCT05426148	PHASE4	COMPLETED	Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female
NCT06031493	PHASE4	UNKNOWN	A Multimodal Intervention Program to Improve Sexual Health and Self-perceived Quality of Life in Patients Treated for Cervical Cancer (PROVIDENCE)
NCT01566240	PHASE3	ACTIVE_NOT_RECRUITING	Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer
NCT02466971	PHASE3	ACTIVE_NOT_RECRUITING	Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
NCT03755739	PHASE2/PHASE3	RECRUITING	Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
NCT04422366	PHASE3	RECRUITING	Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
NCT04537156	PHASE3	ACTIVE_NOT_RECRUITING	Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
NCT04723875	PHASE3	ACTIVE_NOT_RECRUITING	Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline
NCT04733820	PHASE3	RECRUITING	Clinical Efficacy of Adjuvant Chemotherapy in Patients With Locally Advanced Cervical Cancer Who Did Not Meet the NCCN Guidelines for Adjuvant Treatment After NACT Combined With Surgery
NCT04895020	PHASE3	RECRUITING	Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
NCT04906993	PHASE3	ACTIVE_NOT_RECRUITING	Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer
NCT04974346	PHASE3	RECRUITING	Para-aortic Prophylactic Irradiation for Locally Advanced Cervical Cancer
NCT04982237	PHASE3	ACTIVE_NOT_RECRUITING	A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CISPLATIN	4	137
HUMAN PAPILLOMAVIRUS, L1 PROTEIN VIRUS LIKE PARTICLES	4	11
TOPOTECAN	4	9
GEMCITABINE	4	6
TISOTUMAB VEDOTIN	4	5
HYDRALAZINE	4	3
VINORELBINE	4	3
FLUOROURACIL	4	2
IFOSFAMIDE	4	2
INDOCYANINE GREEN ACID FORM	4	2
BLEOMYCIN SULFATE	4	1
BUPROPION HYDROCHLORIDE	4	1
DALTEPARIN SODIUM	4	1
EPOETIN ALFA	4	1
EPOETIN BETA	4	1
FERROUS FUMARATE	4	1
FLUCICLOVINE F18	4	1
MITOMYCIN	4	1
NICOTINE	4	1
OCTREOTIDE ACETATE	4	1
PEMBROLIZUMAB	4	1
VINBLASTINE SULFATE	4	1
VINCRISTINE SULFATE	4	1
VINDESINE	4	1
TRIAPINE	3	4
TIRAPAZAMINE	3	3
MAGNESIUM VALPROATE	3	2
RIVOCERANIB	3	2
ARUNDINE	3	1
FENRETINIDE	3	1

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 4 predictive associations from 4 curated evidence items; also 3 prognostic, 1 oncogenic.

Molecular subtype	Therapy	Effect	Level	CIViC
XRCC1 Q399R	Cisplatin + Carboplatin	Sensitivity/Response	CIViC B	EID673
CD44 CD44v6	Cisplatin	Resistance	CIViC B	EID9481
PIK3CA E545K	Cisplatin	Resistance	CIViC D	EID2985
PIK3CA E545K	Cisplatin + Ionizing Radiotherapy	Resistance	CIViC D	EID8112